We envision that cancer cells with chromosomal instabilities, including chromosome rearrangement, dysregulation in genome maintenance mechanisms (e.g., BRCA mutations), or aberrations in oncogene/tumor suppressor pathways, such as Myc amplification or loss of TP53 and Rb, will be more responsive to our combination treatment. This evidence concerns the gene RB1 and cancer.